Document is current
Any future updates will be listed below
-
Authors
Rüfer, Axel https://orcid.org/0000-0003-2617-1724
Nilius, Henning https://orcid.org/0000-0002-1323-3116
Hermine, Olivier
Niedoszytko, Marek
Oude Elberink, Joanne N. G.
Bonadonna, Patrizia
Shoumariyeh, Khalid
Gulen, Theo
Hartmann, Karin
Sabato, Vito
Angelova-Fischer, Irena
Baffoe, Daniel
Christen, Deborah
Belloni Fortina, Anna
Breynaert, Christine
Brockow, Knut
von Bubnoff, Nikolas https://orcid.org/0000-0001-9593-8947
Bumbea, Horia
van Daele, Paul
Doubek, Michael https://orcid.org/0000-0002-1269-6282
Dybedal, Ingunn
Elena, Chiara
Fokoloros, Christos
Górska, Aleksandra
Heizmann, Marc
Jentzsch, Madlen https://orcid.org/0000-0002-2270-0804
Klein, Saskia https://orcid.org/0000-0001-8847-2704
Lübke, Johannes https://orcid.org/0000-0003-0767-1504
Mattsson, Mattias
Mulder, André
Panse, Jens https://orcid.org/0000-0001-6316-3112
Schug, Tanja Daniela
Sciumè, Mariarita
Stefan, Alex
Sztormowska, Marlena
Várkonyi, Judit
Wortmann, Friederike https://orcid.org/0000-0002-8684-1710
Yavuz, Akif Selim
Sperr, Martina
Gotlib, Jason https://orcid.org/0000-0001-8253-6156
Reiter, Andreas https://orcid.org/0000-0002-7718-6507
Triggiani, Massimo
Sperr, Wolfgang R.
Valent, Peter https://orcid.org/0000-0003-0456-5095
- License Information
-
More Information
Article History
Received: 20 July 2024
Revised: 2 November 2024
Accepted: 11 December 2024
First Online: 15 January 2025
Competing interests
: Conflicts of interest declared by the co-autors: Axel Rüfer: Advisory boards: Blueprint Medicines; Oliver Hermine: Research funding support from AB science and Novartis. Advisory board of AB science; Patrizia Bonadonna: Honoraria: Blueprint Medicines; Karin Hartmann: Lectures/consultancy: ALK, Allergopharma, BioCryst, Blueprint Medicines, Cogent, KalVista, Leo, Menarini, Novartis, Pfizer, Sanofi, Takeda, Thermo Fisher; Vito Sabato: Advisory boards: Blueprint Medicines, Cogent, Novartis, Telios. Honoraria: Thermo Fisher; Knut Brockow: Advisory board and honoraria: Blueprint Medicines; Nikolas von Bubnoff: Honoraria Novartis, Takeda, Astra Zeneca, Janssen-Cilag; Paul van Daele: Lectures/consultancy: Novartis, involved in clinical trials for Cogent Biosciences and Blueprint Medicines; Ingunn Dybedal: Advisory board and honoraria: Blueprint Medicines; Chiara Elena: Advisory board and honoraria: Blueprint Medicines, Gilead; Marc Heizmann: Advisory board and honoraria: Novartis; Jens Panse: Advisory board and honoraria: Blueprint Medicines, Novartis, Deciphera; Friederike Wortmann: Advisory board and honoraria: Blueprint Medicines, Novartis, Pierre Fabre, Abbvie; Jason Gotlib: Research Grant (funds for administration of clinical trials): Novartis, Blueprint Medicines, Deciphera, Cogent Biosciences; Advisory Board and Honoraria: Blueprint Medicines, Novartis, Deciphera, Cogent Biosciences; Reimbursement of travel expenses: Novartis, Blueprint Medicines; Andreas Reiter: Honoraria: Novartis, Blueprint Medicines, Incyte, Celgene/Bristol Myers Squibb, AOP Orphan Pharmaceuticals, GlaxoSmithKline, AbbVie; Consulting or Advisory Role: Novartis, Blueprint Medicines, Incyte, Celgene/Bristol Myers Squibb, AOP Orphan Pharmaceuticals, AbbVie; Massimo Triggiani: Advisory Board and Honoraria: Blueprint Medicines, Novartis; Wolfgang R. Sperr: Honoraria from AbbVie, Astellas, Blueprint, BMS-Celgene, Daiichi Sankyo, Deciphera, Incyte, Jazz Pharmaceuticals, Laboratoires Delbert, Novartis, Otsuka, Pfizer, Servier, Stemline, Thermo Fisher; Peter Valent: 1. Advisory board - honoraria: AOP Orphan, Blueprint, Cogent, Delbert, Incyte, Novartis, PentaBase, Pfizer, Stemline. 2. Research grant: AOP Orphan, Pfizer. The remaining co-authors declared no conflict of interest.
: All methods were performed in accordance with the relevant guidelines and regulations. The ECNM registry study was approved by the responsible local ethics committee of each participating ECNM center. Written informed consent was obtained from all patients included in the ECNM registry.
